查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579346

侵袭性纤维瘤病市场：按治疗类型、分销管道和最终用户划分 - 全球预测 2025-2030

Aggressive Fibromatosis Market by Treatment Type (Non-Surgical Treatment, Surgical Treatment), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，侵袭性纤维瘤病市场估值为27.4亿美元，预计2024年将达29亿美元，复合年增长率为5.88%，到2030年将达41亿美元。

侵袭性纤维瘤病，也称为硬纤维瘤，是一种罕见的局部侵袭性肿瘤，由肌肉神经结构引起，并且不会转移。侵袭性纤维瘤病市场范围主要集中在有效治疗方法的开拓、应用和商业化，重点是手术干预、药物治疗以及标靶治疗和免疫治疗等先进治疗方法。由于术后復发和有效药物治疗有限，该疾病是一个临床挑战。除其他因素外，对新治疗方法的需求是由于需要预防復发和控制发病率而不产生过度副作用。最终使用范围主要针对患者寻求诊断和治疗的医院、专科诊所和癌症治疗中心。该市场的主要成长动力包括疾病意识的提高、诊断成像技术的进步以及对研发更有效治疗方法的兴趣日益浓厚。潜在的商机包括开发非侵入性治疗方法、扩展到医疗需求未满足的新兴市场以及利用生物技术的创新药物输送系统。然而，治疗成本上升、疾病的罕见性可能限制市场规模以及给新参与企业带来挑战的监管障碍等限制因素。罕见疾病研究的资金筹措限制进一步影响成长前景。分子遗传学的针对性研究、新药配方的稳健临床试验以及全球机构之间共用知识的合作研究为创新和业务成长提供了可行的途径。儘管该市场是利基市场，但成长是由癌症研究的技术进步和孤儿药研发的策略重点所推动的。简而言之，对研究的大量投资，加上对教育和患者支持的策略重点，可能会显着增强市场活力。

主要市场统计
基准年[2023] 27.4亿美元
预测年份 [2024] 29亿美元
预测年份 [2030] 41亿美元
复合年增长率（%） 5.88%

市场动态：针对快速发展的侵袭性纤维瘤病市场揭示的关键市场洞察

供需的动态交互作用正在改变积极的纤维瘤病市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 提高医疗保健提供者的意识并提高侵袭性纤维瘤病的诊断准确性
    • 监管支持和孤儿药指定，以加速罕见疾病治疗的开发
    • 扩大製药公司、研究机构和学术中心之间的合作和伙伴关係，加速新治疗方法的开发
  • 市场限制因素
    • 开发和销售新治疗方法，尤其是针对特定疾病
  • 市场机会
    • 关于侵袭性纤维瘤病遗传和分子基础的医学研究和技术进展
    • 整合远端医疗、行动医疗应用程式和穿戴式装置等数位健康技术，以监测治疗反应和患者依从性
  • 市场挑战
    • 侵袭性纤维瘤病的治疗选择和标靶治疗有限

波特的五力：驾驭激进的纤维瘤市场的策略工具

波特的五力架构是了解侵袭性纤维瘤病市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解侵袭性纤维瘤市场的外部影响

外部宏观环境因素在塑造侵袭性纤维瘤病市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解激进的纤维瘤市场的竞争格局

对侵袭性纤维瘤病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵侵袭性纤维瘤病市场供应商的绩效评估

FPNV 定位矩阵是评估侵袭性纤维瘤市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了侵袭性纤维瘤病市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对侵袭性纤维瘤病市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高医护人员的认识并更准确地诊断侵袭性纤维瘤病
      • 监管支持和孤儿药指定，以加速罕见疾病治疗方法的开发
      • 扩大製药公司、研究机构和学术中心之间的合作和伙伴关係，加速新治疗方法的开发
    • 抑制因素
      • 开发新治疗方法并将其推向市场需要高昂的研发成本，尤其是针对小众疾病。
    • 机会
      • 关于侵袭性纤维瘤病遗传和分子基础的医学研究和技术进展
      • 整合远端医疗、行动医疗应用程式和穿戴式装置等数位健康技术，以监测治疗反应和患者依从性
    • 任务
      • 侵袭性纤维瘤病的治疗选择和标靶治疗有限
  • 市场区隔分析
    • 治疗类型：非手术治疗因其侵入性较小而越来越受青睐
    • 最终用户：对门诊手术中心提供微创手术的需求日益增长。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的侵袭性纤维瘤病市场

  • 非手术治疗
    • 冷冻疗法
    • 药物治疗
    • 放射治疗
    • 射频消融术
  • 手术治疗
    • 保守手术
    • 根治性切除手术

第七章 激进的纤维瘤市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第 8 章 激进的纤维瘤病市场：按最终用户

  • 门诊手术中心
  • 医院
  • 研究/学术机构
  • 专科诊所

第九章美洲激进的纤维瘤病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区侵袭性纤维瘤病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 11 章：欧洲、中东和非洲激进的纤维瘤市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 根据 3 期 DeFi 试验的结果，欧洲药品管理局已核准SpringWorks Therapeutics 的 nirogacestat 申请，这是一种针对硬纤维瘤的突破性治疗方法。
    • SpringWorks Therapeutics 的 nirogacestat MAA 已获得 EMA核准，为欧盟核准的首个硬纤维瘤治疗方法铺平了道路，3 期试验结果显示出显着的临床益处。
    • Immunome 以 5,000 万美元从 Ayala Pharmaceuticals 收购了 3 期伽马分泌酶抑制剂 AL102，以加强其癌症治疗组合和临床结果。
  • 战略分析和建议

公司名单

  • 4D Molecular Therapeutics
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurinia Pharmaceuticals Inc.
  • Bayer AG
  • Bioporto Diagnostics A/S
  • Boston Scientific Corporation
  • Celgene Corporation（a Bristol-Myers Squibb Company）
  • Eli Lilly and Company
  • Epizyme, Inc.
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Ltd.
  • Infinity Pharmaceuticals, Inc.
  • Johnson & Johnson Service, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Oncoheroes Biosciences Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SpringWorks Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-8D2A8051067F

The Aggressive Fibromatosis Market was valued at USD 2.74 billion in 2023, expected to reach USD 2.90 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 4.10 billion by 2030.

Aggressive fibromatosis, also known as desmoid tumors, is a rare type of locally invasive tumor which arises from the musculo-aponeurotic structures and does not metastasize. The market scope for aggressive fibromatosis primarily revolves around the development, application, and commercialization of effective therapies, emphasizing surgical interventions, pharmacological treatments, and advanced therapeutic approaches such as targeted therapy and immunotherapy. This condition notoriously poses a clinical challenge given its recurrence post-surgery and limited effective pharmacotherapy. The necessity for novel treatment regimens can be particularly attributed to the need to prevent recurrence and manage morbidity without excessive adverse effects. The end-use scope primarily targets hospitals, specialty clinics, and cancer treatment centers where patients seek diagnosis and treatment. Key growth drivers in this market include heightened awareness about the condition, advancements in diagnostic imaging techniques, and the increasing interest in research and development for more effective therapeutic methods. Potential opportunities lie in developing non-invasive therapies, expanding into emerging markets with unmet medical needs, and leveraging biotechnology for innovative drug delivery systems. Nonetheless, the market faces limitations such as high treatment costs, the rarity of the condition which may limit market size, and regulatory hurdles which pose challenges to new market entrants. Funding constraints for research into rare diseases further impact growth prospects. For innovation and business growth, targeted research in molecular genetics, robust clinical trials for novel drug formulations, and collaborations for knowledge sharing among global institutions offer viable pathways. The market is largely niche but poised for growth driven by technological advances in oncology research and a strategic focus on orphan drug development. In essence, substantial investment in research, coupled with a strategic focus on education and patient advocacy, could significantly enhance market dynamics.

KEY MARKET STATISTICS
Base Year [2023] USD 2.74 billion
Estimated Year [2024] USD 2.90 billion
Forecast Year [2030] USD 4.10 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aggressive Fibromatosis Market

The Aggressive Fibromatosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
    • Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
    • Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
  • Market Restraints
    • High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
  • Market Opportunities
    • Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
    • Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
  • Market Challenges
    • Limited treatment options and targeted therapies for aggressive fibromatosis

Porter's Five Forces: A Strategic Tool for Navigating the Aggressive Fibromatosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aggressive Fibromatosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aggressive Fibromatosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aggressive Fibromatosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aggressive Fibromatosis Market

A detailed market share analysis in the Aggressive Fibromatosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aggressive Fibromatosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aggressive Fibromatosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aggressive Fibromatosis Market

A strategic analysis of the Aggressive Fibromatosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aggressive Fibromatosis Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, AbbVie Inc., Amgen Inc., AstraZeneca plc, Aurinia Pharmaceuticals Inc., Bayer AG, Bioporto Diagnostics A/S, Boston Scientific Corporation, Celgene Corporation (a Bristol-Myers Squibb Company), Eli Lilly and Company, Epizyme, Inc., Exelixis, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Infinity Pharmaceuticals, Inc., Johnson & Johnson Service, Inc., Medtronic plc, Merck & Co., Inc., Novartis AG, Oncoheroes Biosciences Inc., Pfizer Inc., Sanofi S.A., SpringWorks Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Aggressive Fibromatosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Non-Surgical Treatment and Surgical Treatment. The Non-Surgical Treatment is further studied across Cryoablation, Pharmacological Therapies, Radiation Therapy, and Radiofrequency Ablation. The Surgical Treatment is further studied across Conservative surgery and Radical resection.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, Research & Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
      • 5.1.1.2. Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
      • 5.1.1.3. Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
      • 5.1.3.2. Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
    • 5.1.4. Challenges
      • 5.1.4.1. Limited treatment options and targeted therapies for aggressive fibromatosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Growing preference for non-surgical treatments owing to their minimally invasive nature
    • 5.2.2. End User: Increasing need for ambulatory surgical centers offering minimally invasive surgical interventions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Aggressive Fibromatosis Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Surgical Treatment
    • 6.2.1. Cryoablation
    • 6.2.2. Pharmacological Therapies
    • 6.2.3. Radiation Therapy
    • 6.2.4. Radiofrequency Ablation
  • 6.3. Surgical Treatment
    • 6.3.1. Conservative surgery
    • 6.3.2. Radical resection

7. Aggressive Fibromatosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Aggressive Fibromatosis Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Research & Academic Institutes
  • 8.5. Specialty Clinics

9. Americas Aggressive Fibromatosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Aggressive Fibromatosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Aggressive Fibromatosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. European Medicines Agency validates SpringWorks Therapeutics' application for nirogacestat, a groundbreaking treatment for desmoid tumors, following phase 3 DeFi trial results
    • 12.3.2. SpringWorks Therapeutics' nirogacestat MAA accepted by EMA, paving the way for first EU-approved therapy for desmoid tumors, showcasing significant clinical benefits from Phase 3 trial outcomes
    • 12.3.3. Immunome acquires Phase 3 gamma secretase inhibitor AL102 from Ayala for $50M to enhance cancer therapy portfolio and clinical outcomes
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Molecular Therapeutics
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Aurinia Pharmaceuticals Inc.
  • 6. Bayer AG
  • 7. Bioporto Diagnostics A/S
  • 8. Boston Scientific Corporation
  • 9. Celgene Corporation (a Bristol-Myers Squibb Company)
  • 10. Eli Lilly and Company
  • 11. Epizyme, Inc.
  • 12. Exelixis, Inc.
  • 13. GlaxoSmithKline plc
  • 14. Hoffmann-La Roche Ltd.
  • 15. Infinity Pharmaceuticals, Inc.
  • 16. Johnson & Johnson Service, Inc.
  • 17. Medtronic plc
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Oncoheroes Biosciences Inc.
  • 21. Pfizer Inc.
  • 22. Sanofi S.A.
  • 23. SpringWorks Therapeutics, Inc.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. AGGRESSIVE FIBROMATOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AGGRESSIVE FIBROMATOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AGGRESSIVE FIBROMATOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AGGRESSIVE FIBROMATOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AGGRESSIVE FIBROMATOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY CONSERVATIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADICAL RESECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. AGGRESSIVE FIBROMATOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. AGGRESSIVE FIBROMATOSIS MARKET, FPNV POSITIONING MATRIX, 2023